BioSpecifics Technologies Corp

Type: Company
Name: BioSpecifics Technologies Corp
First reported Apr 02 2014 - Updated Apr 02 2014 - 3 reports

BioSpecifics Technologies Corp. to Present at the 13th Annual Needham Healthcare Conference

LYNBROOK, N.Y.The presentation will take place on Wednesday, April 9, 2014About BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to ... [Published Benzinga.com - Apr 02 2014]
First reported Mar 30 2014 - Updated Mar 30 2014 - 1 reports

New Market Report Now Available: Liposarcoma Global Clinical Trials Review, H1, 2014

(live-PR.com) - GlobalData's clinical trial report, "Liposarcoma Global Clinical Trials Review, H1, 2014" provides data on the Liposarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on ... [Published Live-PR.com - Mar 30 2014]
First reported Mar 14 2014 - Updated Mar 14 2014 - 1 reports

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) ... [Published NewsRX - Mar 14 2014]
First reported Mar 12 2014 - Updated Mar 12 2014 - 1 reports

BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2013 Financial Results

By a News Reporter-Staff News Editor at Biotech Week -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX(®) in the U.S. and XIAPEX(®) in the EU, announced ... [Published HispanicBusiness.com - Mar 12 2014]
First reported Feb 27 2014 - Updated Feb 28 2014 - 1 reports

BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 6, 2014

LYNBROOK, N.Y., Feb. 27, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that ... [Published PR Newswire: Health - Feb 27 2014]
First reported Feb 19 2014 - Updated Feb 21 2014 - 1 reports

BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences

LYNBROOK, N.Y., Feb. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that ... [Published PR Newswire: General Business - Feb 19 2014]
First reported Nov 22 2013 - Updated Nov 22 2013 - 1 reports

8-K - BIOSPECIFICS TECHNOLOGIES CORP (0000875622) (Filer)

Filed: 2013-11-22 AccNo: 0001062993-13-005992 Size: 9 KBItem 1.01: Entry into a Material Definitive AgreementItem 1.02: Termination of a Material Definitive Agreement ... [Published SEC Filings - Nov 22 2013]

Quotes

"2013 was a very productive and momentous year for BioSpecifics as we continued to demonstrate the vast potential of injectable collagenase or CCH. Perhaps most notable in 2013 was on the commercial front with the FDA approval of XIAFLEX as the first... We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3."
"We continued to make progress with pipeline programs in 2013 as well. Within our own pipeline, we reported compelling preclinical data in a new potential indication, uterine fibroids, and plan to report more preclinical data from ongoing studies with Duke Medicine in the second quarter of 2014. Additionally, we reported data from Phase 2 trials in both human and canine lipomas. We are finalizing the full study report from the Chien-804 study and will await Auxilium's decision whether or not to opt-in to the licensing rights for this indication. For the human lipoma indication, we plan to initiate a placebo-controlled trial in the first half of 2014, following positive results reported in January 2014 , which met the primary endpoint of demonstrating efficacy of CCH in reducing the visible surface area of the lipoma. For our partnered indications, Auxilium initiated a Phase 2a trial in cellulite and a Phase 2b trial in frozen shoulder and we can expect top-line data from both studies in the first quarter of 2015."

More Content

All (11) | News (6) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (0) | Press Releases (2)
sort by: Date | Relevance
BioSpecifics Technologies Corp. to Present at t... [Published Benzinga.com - Apr 02 2014]
BioSpecifics Technologies Corp. to Present at t... [Published TickerTech.com - Apr 02 2014]
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: Health - Apr 02 2014]
New Market Report Now Available: Liposarcoma Gl... [Published Live-PR.com - Mar 30 2014]
BioSpecifics Technologies Corp. Reports Fourth ... [Published NewsRX - Mar 14 2014]
BioSpecifics Technologies Corp. Reports Fourth ... [Published HispanicBusiness.com - Mar 12 2014]
BioSpecifics Technologies Corp. Reports Fourth ... [Published Financial Services - Mar 06 2014]
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - Feb 27 2014]
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: General Business - Feb 19 2014]
The Zacks Analyst Blog Highlights:United Therap... [Published Financial Services - Jan 03 2014]
8-K - BIOSPECIFICS TECHNOLOGIES CORP (000087562... [Published SEC Filings - Nov 22 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
BioSpecifics Technologies Corp. to Present at t... [Published PR Newswire: Health - Apr 02 2014]
LYNBROOK, N.Y., April 2, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that ...
BioSpecifics Technologies Corp. to Host Confere... [Published PR Newswire: Health - Feb 27 2014]
LYNBROOK, N.Y., Feb. 27, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that ...
BioSpecifics Technologies Corp. Announces Prese... [Published PR Newswire: General Business - Feb 19 2014]
LYNBROOK, N.Y., Feb. 19, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today announced that ...
1

Press Releases

sort by: Date | Relevance
BioSpecifics Technologies Corp. Reports Fourth ... [Published Financial Services - Mar 06 2014]
The Zacks Analyst Blog Highlights:United Therap... [Published Financial Services - Jan 03 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.